Innospec (NASDAQ:IOSP - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of $1.36 per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Innospec (NASDAQ:IOSP - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The specialty chemicals company reported $1.39 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.02. Innospec had a net margin of 7.90% and a return on equity of 14.15%. The business had revenue of $435.00 million during the quarter, compared to analysts' expectations of $468.73 million. During the same quarter in the prior year, the company earned $1.28 EPS. The firm's quarterly revenue was down 9.5% on a year-over-year basis. On average, analysts expect Innospec to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Innospec Price Performance
Shares of Innospec stock traded down $0.74 during trading hours on Tuesday, hitting $109.28. The company's stock had a trading volume of 64,963 shares, compared to its average volume of 106,929. The stock has a 50 day moving average of $111.49 and a 200 day moving average of $119.30. Innospec has a 12 month low of $96.89 and a 12 month high of $133.71. The company has a market capitalization of $2.73 billion, a PE ratio of 18.32 and a beta of 1.07.
Analyst Ratings Changes
Separately, StockNews.com lowered Innospec from a "strong-buy" rating to a "buy" rating in a research report on Thursday, August 8th.
Get Our Latest Stock Report on IOSP
Insiders Place Their Bets
In other news, CFO Ian Cleminson sold 3,398 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $114.74, for a total transaction of $389,886.52. Following the transaction, the chief financial officer now directly owns 12,996 shares in the company, valued at $1,491,161.04. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.35% of the company's stock.
Innospec Company Profile
(
Get Free Report)
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.
Featured Stories
Before you consider Innospec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innospec wasn't on the list.
While Innospec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.